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Abstract
Background: The influenza virus is still one of the most important respiratory risks affecting humans which require
effective treatments. In this case, traditional medications are of interest. HESA-A is an active natural biological
compound from herbal-marine origin. Previous studies have reported that the therapeutic properties of HESA-A are
able to treat psoriasis vulgaris and cancers. However, no antiviral properties have been reported.
Methods: This study was designed to investigate the potential antiviral properties of HESA-A and its effects in
modulating TNF-a and IL-6 cytokine levels. HESA-A was prepared in normal saline as a stock solution (0.8 mg/ml,
pH = 7.4). Percentages of cell survival when exposed to different concentrations of HESA-A at different time
intervals was determined by MTT assay. To study the potential antiviral activity of HESA-A, Madin-Darby Canine
Kidney (MDCK) cells were treated with the effective concentration (EC50) of HESA-A (0.025 mg/ml) and 100 TCID50/
0.1 ml of virus sample under different types of exposure.
Results: Based on the MTT method and hemagglutination assay (HA), HESA-A is capable of improving cell viability
to 31% and decreasing HA titre to almost 99% in co-penetration exposures. In addition, based on quantitative real-
time PCR (qRT-PCR) and enzyme-linked immunosorbent assay (ELISA), it was found that HESA-A causes decrements
in TNF-a and IL-6 cytokine expressions, which was significant for TNF-a (p ≤ 0.05) but not for IL-6.
Conclusion: In conclusion, HESA-A was effective against influenza infection through suppressing cytokine
expression.
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Background
Influenza virus A, a member of the Orthomyxoviridae
family, is one of the most important causes of acute
contagious respiratory diseases worldwide. Its infectivity
is increasing due to various drifts and shifts of genetic
mutations that cause constant alterations of the anti-
body-targeted surface glycoproteins. This property
makes it extremely difficult to develop effective vaccines
and specific drugs [1]. Even conventional drugs such as
Amantadine and Oseltamivir, that are able to control
t h ee n t r a n c ea n dr e l e a s eo ft h ev i r u sf r o mt h eh o s tc e l l
based on the viral protein structures, are not effective
enough and have shown many cases of side effects and
drug resistances [2]. So, there have been suggestions in
switching to traditional medication for influenza disease
treatment. HESA-A is an active natural biological com-
pound from herbal-marine origin, with a general com-
position of inorganic, organic and aqueous fractions [3].
Previous studies have reported the therapeutic proper-
ties of HESA-A against psoriasis vulgaris, breast cancer
and choroidal metastasis [4,5]. However, there is no
published evidence on its antiviral activity against influ-
enza virus infectivity.
One of the most important factors which contributed
to the pathogenesis of influenza infection has been
shown to be cytokine dysregulation. Influenza viruses,
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tion of pro-inflammatory cytokines such as TNF-a and
IL-6, that in turn, cause immune system uncontrolled
responses that lead to inflammation [6,7]. Therefore,
there have been suggestions that anti-inflammatory and
immunomodulatory agents could be effective alterna-
tives to vaccines and antiviral agents against influenza.
In this study, the antiviral effect of HESA-A against
influenza virus infection was evaluated in vitro.
Results
Cell viability
MDCK cells viability was determined after different
times of exposure to different concentrations of HESA-
A through MTT at an optical density of 540 nm. The
results showed that HESA-A had no cytotoxic effect on
the cells for concentration of up to 0.05 mg/ml. The
EC50 of this compound was calculated from the MTT
results by two-way ANOVA analysis at 0.025 mg/ml,
with no significant toxicity on cell viability (Table 1).
HESA-A inhibitory effect on influenza virus
In this experiment, there were increments in the optical
densities (ODs) measured after running the MTT assay
for different exposures, compared with the virus-treated
sample without HESA-A. The results for the virus treat-
ment, as well as post-, pre- and co-penetration treat-
ments (mean ± SD) are 0.54 ± 0.11, 0.61 ± 0.10, 0.65 ±
0.10 and 0.71 ± 0.09, respectively. However, as shown in
Figure 1, the significant increment in OD (p ≤ 0.05) was
related to the co-penetration exposure. The ODs were
also analyzed to examine the percentage of HESA-A
protection in combination treatments compared to
Amantadine treatments. As shown in Figure 2, the
ranges of ODs were significantly higher in all types of
treatments, especially the co- & pre- treatments, than
the Amantadine-treated samples. In addition, the HESA-
A co-penetration treatment showed the highest OD,
nearly three times more than the Amantadine co-
treatment.
Hemagglutination assay results
Based on hemagglutination titration, the inhibitory effect
of HESA-A on viral activity was shown through a signif-
icant reduction in HA titre in all combination treat-
ments. Notably, in the co-penetration treatment, the HA
titre decreased by 98.75% compared to the untreated
sample (Table 2).
Absolute quantification
The HESA-A effects on viral genome load and inflam-
matory cytokine levels were shown by log10 copy num-
ber decrements in treatments which were calculated
through absolute quantification. Quantitative analysis on
the M2 gene of influenza virus A PCR products exposed
Table 1 Mean MTT results of treatments with different
concentrations of HESA-A
Sample (mg/ml) Mean ± SD
0.8 0.21 ± 0.21٭
0.4 0.26 ± 0.24٭
0.2 0.33 ± 0.24٭
0.1 0.43 ± 0.25٭
0.05 0.51 ± 0.22٭
0.025 0.69 ± 0.20
0.013 0.73 ± 0.18
0.0 1.00 ± 0.00
Values (averages of 4 independent experiments) showed cytotoxicity of
different concentrations of HESA-A at different exposure time (24, 48 &72 hr)
on MDCK cells (mean ± SD). CC50 and EC50 are determined as 0.05 and 0.025
mg/ml, respectively.: ٭Significantly different from values obtained for HESA-A-
treated samples compared to untreated sample (p < 0.05)
Figure 1 MTT optical densities for cell viability in response to
different types of exposure of HESA-A and virus (averages of 4
independent tests) (mean ± SD). *: Significantly different from
values obtained for the co-penetration treatment compared to the
virus untreated sample (p < 0.05).
Figure 2 Comparison of the percent of protection of HESA-A
and Amantadine on cell viability. Data analyzed by SPSS, one
way ANOVA are averages of 4 independent experiments (mean ±
SD). HESA-A showed a higher degree of protection towards cell
viability in comparison with Amantadine treatments. It was
significantly higher in co- and pre-penetration treatments. *:
Significantly different from values obtained for co- & pre-penetration
treatments compared to Amantadine treatments (p < 0.05).
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showed statistically significant decrements in viral load
compared to the virus sample (Table 3).
For absolute quantification of the cytokine genes, TNF-a
and IL-6 PCR product analyses showed considerable
decrements in log10 copy numbers in all types of expo-
sures. The decrement in TNF-a gene load was significant
only in direct exposure of HESA-A to the virus (p < 0.05),
but not in the pre- & post-penetration exposures, while
IL-6 decrements were not significant (Table 4).
Cytokine detection using ELISA assay
TNF-a and IL-6 protein levels in the supernatants of
MDCK cell cultures at 24 and 48 hour after exposure
were not detected (data not shown), but after 72 hour
of treatments, virus-treated samples show significantly
higher expression than HESA-treated supernatants. The
data was analyzed using One-way ANOVA followed by
Tukey post-hoc test (Table 5).
Discussion and conclusion
The influenza virus causes severe respiratory diseases
that remains as a leading source of annual morbidity [8].
The discovery and development of novel anti-influenza
compounds, preferably of natural origin, are required to
prevent and treat potential influenza pandemics. Existing
therapeutic antiviral agents have limited clinical effi-
ciency with many toxic side effects, but antiviral com-
pounds of natural origin are more easily available and are
mostly nontoxic [9,10].
It has been shown that an influenza infection triggers
the induction of pro-inflammatory cytokines which
activate GTPase proteins by isoprenylation and begins
the process of recognizing ssRNA [11] to express the
target genes for cytokines, such as IL-1, IL-6, TNF-a
and IFN-g. However, the increased level of pro-inflam-
matory cytokines after an influenza virus infection,
which is caused by an over-responsive immune system,
sometimes causes hypercytokinemia. Hypercytokinemia
is the systemic expression of a strong immune system
and is a potentially lethal reaction which consists of a
positive feedback between cytokines and immune cells
that, in turn, causes lung inflammation [7,8,12,13]. The
most important pro-inflammatory cytokines that are
responsible for these reactions are IL-6 and TNF-a.
These cytokines are pleiotropic inflammatory cytokines
that play important roles in metabolism, apoptosis, mas-
sive systemic effects and inflammation, which are hall-
marks of influenza [14-16].
HESA-A is a natural compound of herbal-marine origin
which contains inorganic, organic and aqueous fractions
with a wide range of therapeutic applications [4,17,18]. In
this study, the interaction between HESA-A and influenza
virus A/H1N1 was evaluated. HESA-A was not toxic on
MDCK cells at up to 0.05 mg/ml. As calculated from the
MTT results by two-way ANOVA test, the EC50 of this
compound was obtained at 0.025 mg/ml, with no cyto-
toxic effect on the cells. The optical densities obtained
from the MTT assay showed that co-penetration and pre-
penetration treatments had 86.92% ± 9.79 and 69.17% ±
11.8 of protection, respectively. These treatments were
more protective (p ≤ 0.05) against viral cytopathic effects
in comparison with the other exposures, even with differ-
ent Amantadine treatments. Meanwhile, HA results
showed a significant decrease in HA titre in all combina-
tion treatments compared to the positive control of a
virus-treated sample. From these results, it is postulated
that HESA-A may interfere with viral membrane fusion by
inhibiting penetration or adsorption through HA glyco-
protein interference.
The antiviral effects of HESA-A on influenza viral load
and cytokine levels in MDCK cell cultures were ana-
lyzed using quantitative real-time PCR assay. This tech-
nique, which provides absolute copy numbers of the
template, is a reliable and more accurate tool compared
Table 2 Hemagglutination assay results evaluating the
antiviral activity of HESA-A against influenza virus A
Treatment Mean ± SD
Virus sample 45.71 ± 15.83
Post-penetration 6.86 ± 11.65*
Pre-penetration 3.43 ± 5.83*
Co-penetration 0.57 ± 1.40*
Values are averages of 4 independent HA assays
*: Significantly different from values obtained for HESA-A-treated samples
compared to untreated sample (p ≤ 0.05)
Table 3 M2 Log10 copy numbers at different treatments
Sample Ct (Mean ± SD) Log10 Copy Numbers (Mean ± SD)
Control 0 ± 0 0 ± 0
Virus 10.900 ± 0.026 12.004 ± 0.003
Co-penetration 11.760 ± 0.044 11.916 ± 0.004*
Pre-penetration 11.737 ± 0.055 11.919 ± 0.006*
Post-penetration 11.593 ± 0.445 11.933 ± 0.045*
Log10 copy numbers relating to Ct values during amplification of the influenza A H1N1 M2 gene were averages of 2 independent repeats in duplicate and
showed significant decrease (p < 0.05) in all combination treatments in comparison with the virus untreated sample
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tity of targeted genes can be evaluated with reasonable
accuracy by using a reliable standard [21]. A standard
curve, constructed from standard concentrations (data
not shown), was used to determine the copy numbers of
target genes related to the Ct value. Significant incre-
ments in the cycle thresholds (Cts) of M2 PCR products
were observed once HESA-A was applied in all types of
combination treatments. The log10 copy numbers, which
were calculated from the concentrations against mean Ct
values, confirmed these significant differences, especially
when HESA-A was applied in the co-penetration treat-
ment. In HESA-A and virus combination treatments,
TNF-a and IL-6 copy numbers, which were calculated
from the standard curves, showed some decrements. The
standard curves were obtained by plotting concentrations
against mean Ct values. Significantly low expression in
TNF-a, but not IL-6, was related to the co-penetration
treatment.
The quantification of cytokines by qRT-PCR was also
analyzed and confirmed using ELISA. It was found that
infection by the virus causes high expression levels of
these pro-inflammatory cytokines, while in all
combination treatments, the expression of these proteins
significantly decreased, especially in co-penetration treat-
ments, which showed 96.51% and 90.77% decrements in
TNF-a and IL-6 protein expression, respectively.
In conclusion, it is possible to limit immune system
over-expression and turn off lung inflammation caused
by influenza infection if proper treatment with HESA-A
is applied. Clinical control can prevent this intense cyto-
kine response through early diagnosis and efficient treat-
ment. Further research on the interaction of HESA-A
active compounds with different parts of cellular and
viral genes are currently underway.
Materials and methods
Cell culture and influenza virus propagation
MDCK cells were grown in Dulbecco’s Modified Eagle’s
Medium (DMEM) (Mediatech Cellgro, USA), supplemen-
ted with 10% Fetal Bovine Serum (FBS) (PAA, Austria)
and 1% Pen/Strep (Mediatech Cellgro, USA) at 37°C in a
humidified incubator. The media was changed two to
three times per week. The influenza vaccine strain, A/New
Jersey/8/76 (H1N1), was purchased from American Type
Culture Collection (ATCC) with the Reference Number
VR-897™. It was propagated in MDCK cells in the pre-
sence of 1 μg/ml of Trypsin_TPCK (Tosylamide Pheny-
lethyl Chloromethyl Keton-treated Trypsin) (Sigma, USA)
to create the working stock. During antiviral evaluations,
media supplemented with FBS was sucked out and the cell
was washed with PBS and then it was treated as needed.
Then media supplemented with Trypsin_TPCK was
added.
HESA-A preparation
HESA-A was kindly provided by Dr. Amrollah Ahmadi,
Tehran University of Medical Sciences, Tehran, IRAN.
In brief, it was dissolved in normal saline, shaken for 30
minutes and filtered to become homogenate. Prior to its
use, the stock solution (0.8 mg/ml, pH 7.4) was steri-
lized through 0.22 μm nylon filter membrane and
diluted with DMEM [22].
Table 4 TNF-a and IL-6 log10 copy numbers in different treatments
TNF-a IL-6
Sample Log10 Copy Numbers (Mean ± SD) Log10 Copy Numbers (Mean ± SD)
Control 10.854 ± 0.051* 11.096 ± 0.137
HESA-A 10.806 ± 0.086* 11.092 ± 0.015
Virus 11.436 ± 0.051 11.464 ± 0.031
Co-penetration 11.244 ± 0.005* 11.104 ± 0.025
Pre-penetration 11.294 ± 0.007 11.258 ± 0.045
Post-penetration 11.447 ± 0.001 11.397 ± 0.397
Log10 copy numbers were obtained from Ct values during the amplification of the TNF-a and IL-6 cytokine genes. Data are averages of 2 independent repeats in
duplicate
*: significantly different compared with the virus untreated sample (p < 0.05)
Table 5 TNF-a and IL-6 protein concentrations in MDCK
culture supernatants (pg/ml) after 72 hr exposure
TNF-a IL-6
Treatment Concentration (Mean ±
SD)
Concentration (Mean ±
SD)
Negative
control
3.94 ± 0.01 2.33 ± 0.00
HESA-A 2.58 ± 0.00 1.33 ± 0.00
Virus 12.88 ± 0.00* 21.67 ± 0.01*
Co-penetration 0.45 ± 0.00 2.00 ± 0.00
Pre-penetration 3.03 ± 0.01 4.00 ± 0.00
Post-
penetration
3.64 ± 0.00 5.00 ± 0.00
Concentrations of TNF-a and IL-6 proteins, as determined by ELISA, are
expressed as pg/ml (N = 6-8) after a 72 hr incubation time,
*: significantly different from mock-inoculated and treated cells in different
experiments (P < 0.05)
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MDCK cells were incubated in 96-well micro-plate (Nunc,
Denmark) for 24 hours at 37°C. Two-fold serial dilutions
of HESA-A were added to the semi-confluent cells in tri-
plicates and incubated at different time intervals. Colori-
metric MTT assay was performed according to Mehrbod
et al. (2009) [23]. The absorbance of color in the solution
was analyzed at 540 nm with micro-plate reader machine
(BioTek EL 800, US) to calculate the 50% cytotoxic con-
centration (CC50), effective concentration (EC50) and via-
bility of the cells by two way ANOVA, SPSS.
Percentage of protection
After one hour of incubation with EC50 of HESA-A in dif-
ferent types of exposure (co-, pre- and post-penetration)
with 100 TCID50 of the virus, the cells were washed with
1X PBS and, then medium supplemented with Tryp-
sin_TPCK was added (100 μl/well). After 48 hours of incu-
bation at 37°C, viabilities of the cells were evaluated by
MTT. Meanwhile, the virus titre was determined by HA
assay [23].
The percentage of protection of HESA-A was calcu-
lated, in Microsoft Office Excel 2010 and SPSS, from the
MTT results of mock-infected and infected cells after 48
hours of exposure, using the following formula:
Percentage of protection = [(ODT)V − (ODC)V]/[(ODC)M − (ODC)V] × 100
where (ODT)V, (ODC)V and (ODC)M imply the
absorbance of the treated sample, the virus-infected
control (no compound) and the negative control (no
virus and no compound), respectively [24].
Hemagglutination assay
To evaluate the presence of the virus in cell culture, in
either treated or non-treated samples, serial dilutions of
the culture media were added to 96-well U-shape
micro-plates. Chicken red blood cells (cRBCs) (0.5%)
were added to each well. The assay was carried out as
described previously by Mehrbod et al. (2009) [23].
RNA extraction and generation of cDNA
For each sample, viral RNA was extracted from 200 μl
of cell culture fluid using Viral Nucleic Acid Extraction
kit II, according to the manufacturer’s instructions
(Geneaid, Taiwan). The extracted RNA was isolated and
re-suspended in 50 μl of sterile RNase-free water.
For cellular RNA extraction, cells were trypsinized and
suspended in 1X PBS. After centrifugation, total RNA
was purified from the cell pellet using GeneJET™ RNA
Purification Kit, according to the procedures (Fermentas,
Canada). Extracted total RNA was diluted in 100 μl
RNase-free water.
Extracted RNAs, in a volume of 10 μl, were added to
each reaction mix of the RevertAid H Minus First Strand
cDNA kit (Fermentas, Canada), including random hex-
amer primers, 5X Reaction buffer, RNase inhibitor and
dNTP mix to a final volume of 20 μl. The mix was incu-
bated at 25°C for 5 min, followed by 42°C for 60 min, and
terminated at 70°C for 5 min. The concentration of the
cDNA templates was measured using the Nanodrop sys-
tem (Implen NanoPhotometer™ Germany). Virus-inocu-
lated and mock-infected samples were considered as
positive and negative controls respectively.
Primer design
Primers for quantitative real-time PCR (qRT-PCR) were
designed and synthesized by First Base Co. Malaysia.
The descriptions of the primers used for the amplifica-
tion of the influenza M2 gene and canine TNF-a and
IL-6 genes are as shown in Table 6.
Quantitative real-time PCR
Real-time PCR reactions were performed in total volume
of 25 μl, using the CFX 96 Real-Time PCR Detection Sys-
tem (Bio-Rad, USA). Maxima SYBR Green/Fluorescein
master mix (2×) (Fermentas, Canada) was used for the
amplification. The reaction mixture, which consisted of a
final concentration of 1× reaction buffer [KCL and (NH4)
2SO4,d N T P ,2 . 5m MM g C l 2, Taq DNA polymerase, SYBR
Green dye I and fluorescein passive reference dye], 0.3 μM
of each primer and 1 μg/μl of cDNA, was prepared in low-
profile 0.2 ml tube strips (Bio-Rad, Hercules, CA, USA).
The thermal cycling program for the M2 and TNF-a
genes consisted of an initial incubation at 95°C for 3 min,
followed by 40 cycles of denaturation at 95°C for 15 s,
annealing at 60°C for 30 s and extension at 72°C for 20 s.
The amplification conditions for the IL-6 gene was one
cycle of initial denaturation at 95°C, followed by 45 cycles
of denaturation at 95°C for 30 s, annealing at 58°C for 30 s
and extension at 72°C for 20 s. Upon amplification com-
pletion, the specificity of the amplified products was con-
firmed using melting curve analysis, whereby the PCR
products were incubated by raising the incubation tem-
perature from 70°C to 90°C with 0.5°C increment per sec-
ond. All the reactions were performed in duplicates and a
mixture containing no cDNA template was used as the
negative control. Data acquisition and analysis were per-
formed using the CFX Manager Version 2.0.
Construction of standards for quantification
For each real-time PCR assay, the cDNA template from
the respective positive control sample was diluted 10-
fold (10
2 copies/μlt o1 0
7 copies/μl) to construct the
standard curves. The Maxima™ SYBR Green/Fluores-
cein qPCR Master Mix Kit (Fermentas, Canada) was
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was generated by plotting the cycle threshold values (Ct)
against the input cDNA copy number (copies/μl) along-
side a non-template control (NTC). The concentration
of cDNA templates was quantified by the Nanodrop sys-
tem (Implen NanoPhotometer™ Germany) and the copy
numbers for the standards were calculated by the fol-
lowing formula [25]:
Number of copies/µl=

6.02 × 1023 
molecules/mole

× DNA concentrations

g/µl

/

Number of bases pairs × 660 daltons

Where 6.02 × 10
23 (molecules/mole) is Avogadro’s
number and 660 daltons is the average weight of a sin-
gle base pair.
IL-6 and TNF-a cytokine assays
An enzyme-linked immunosorbent assay (ELISA) was
used to examine the effects of viral infection and HESA-
A treatments on TNF-a and IL-6 cytokine protein pro-
duction. Quantitative sandwich ELISA was performed
using the Quantikine ELISA kits (R&D Systems, Min-
neapolis, MN) in micro-plates pre-coated with polyclo-
nal antibodies specific for the IL-6 and TNF-a
cytokines. Cell-free supernatants, incubated for 24, 48-
72 hours in different treatments, were collected for cyto-
kine analyses and stored at -80°C until further proces-
sing. The cultures were repeated on at least four
separate occasions, in duplicates. After being washed,
the enzyme reaction yielded a blue color that turned
yellow when the stop solution was added. The strength
of the color relates to the quantity of the cytokines
bound in the first step. Finally, the sample values were
read off the standard curve.
Statistical analysis
The data, expressed as mean ± SD, was gathered and
analyzed using Microsoft Office Excel 2007 and analysis
of variance (ANOVA) (SPSS 18.0). Sample values
between different groups and treatments with p ≤ 0.05
were considered statistically significant.
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